ADGEN is using its patented technology as an umbrella under which it is developping a series of chemical analogs based on the structures of our  lead lipid mobiliser protein, as well as novel phospho-Tau inhibitor compounds. The lead optimization process will result in the production of new  chemical entities (NCEs) for pre-clinical research programs. The final candidates which are bound to be very similar in structure to our key lead  compounds are designed to improve on their current regenerative or inhibiting properties, brain penetration and cardiovascular safety profile. The  production of potent apoE modulators that stimulates brain reinnervation will be used to slow down or stop disease progression, but more  importantly, to delay the onset of the disease in people who are not symptomatic but carry defective “at risk” genes. This represents a clear  practical and achievable mid-term goal. It has been determined that a five years delay in the onset of AD could translate into a reduction of the  prevalence of Alzheimer's disease by 50% in occidental countries over one generation and in a reduction of caring cost (direct and indirect) in  excess of $400 billions worldwide (in 2016 dollars). The worldwide market for such a drug in Alzheimer's disease alone is estimated to be in the  order of $6-12 billion per year.  ADGEN has identified several novel genetic markers for age of onset, disease progression and response to standard therapies in  neurodegenerative diseases and stroke, all linked to the neuronal remodeling pathways. The ADGEN team has also discovered protective  genetic variants that attenuate risk and affect age of onset while providing interesting new therapeutic targets. Dr. Poirier’s research team has  carried out extensive pharmacogenomic programs the past two decades with international pharmas, including Warner-Lambert, Pfizer, Novartis,  Avantis, Servier, Astrazeneca and Bayer, principallly on cognitive enhancer drugs exhibiting different modes of action. These programs have been  associated with compound drug development where a focus was built around individual response to specific therapeutic agents. This approach  has aided the interpretation of marginal drug effects and established a molecular basis for efficacy and safety in several experimental compounds  in randomised, double-blind, clinical trials. Dr. Poirier has also worked with the genomic team at Motorola on experimental devices designed to  perform low-cost genetic profiles to be used in physician offices, an emerging market for both, the US and Europe. The initial research-business  concept holds true today, but in a broader sense. The ADGEN team has a well documented and proprietary knowledge of mechanisms for  neuronal remodeling through the study of neuron degeneration caused by neurodegenerative diseases or trauma. 
Title page Home News Research Gallery Our Team Team publications Contact Public Information Kudos Service Franšais Franšais Service